Sarepta Makes Headway With Phase 2 Program
Sarepta Therapeutics announced additional clinical efficacy and safety data from its Phase 2b program of eteplirsen in patients with Duchenne muscular dystrophy.
Despite taking a slight hit from the collapse in the health care sector in the past quarter, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is still up significantly over the past year and was building momentum early on Thursday. The company announced additional clinical efficacy and safety data from the company’s Phase 2b program of eteplirsen in patients with Duchenne muscular dystrophy (DMD).
So far, the data demonstrated that eteplirsen provided a statistically significant advantage of 151 meters in the ability of study participants to walk at three years, compared with external controls. Additionally, the fourth biopsy data has confirmed the mechanism of action of eteplirsen, which demonstrated exon skipping in all patients and dystrophin production in nearly all patients. Safety data remained consistent with prior results.
Eteplirsen is designed to target the underlying cause of DMD by enabling the production of a functional dystrophin protein in patients with mutations amenable to exon 51 skipping. Roughly 13% of people with DMD are estimated to have a mutation targeted by eteplirsen/exon 51 skipping.
Edward Kaye, M.D., Sarepta’s interim CEO and chief medical officer, said:
We are encouraged by the positive clinical outcomes, such as the statistically significant difference in the 6MWT in eteplirsen-treated patients compared to a control, especially since we see them accompanied by data that continues to demonstrate exon skipping and dystrophin production in most patients. We are committed to bringing eteplirsen and our other investigational exon skipping therapies to patients with DMD and will continue to work with all stakeholders to advance these programs as quickly as possible so we can better address the unmet need for treatments in the DMD community.
Shares of Sarepta closed Wednesday up 0.7%, at $32.11 in a 52-week trading range of $11.33 to $41.47. In early trading indications on Thursday, shares were up 18% at $37.90. The stock has a consensus analyst price target of $41.75.
ALSO READ: 2 Deutsche Bank Health Care Focus Stocks With Big Upside Potential
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
